Scarica l'app Stockscreener
144.99
0.15%
-0.22
Dopo l'orario di chiusura:
144.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$145.21
Aprire:
$146.85
Volume 24 ore:
4.38M
Relative Volume:
0.61
Capitalizzazione di mercato:
$179.99B
Reddito:
$29.45B
Utile/perdita netta:
$8.51B
Rapporto P/E:
21.38
EPS:
6.7823
Flusso di cassa netto:
$9.46B
1 W Prestazione:
+0.74%
1M Prestazione:
-6.45%
6M Prestazione:
+26.57%
1 anno Prestazione:
+27.91%
Intervallo 1D:
$144.20
$148.22
Intervallo di 1 settimana:
$143.49
$149.38
Portata 52W:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
144.99 | 179.99B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Wellington Management Group LLP Has $2.84 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Prudential PLC - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Dodge & Cox Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - Stock Traders Daily
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Analysts Set Expectations for Gilead Sciences Q1 Earnings - MarketBeat
Martingale Asset Management L P Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Invesco Ltd. Purchases 1,618,453 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial - Yahoo Finance Singapore
How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story - finance.yahoo.com
[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD) - MarketBeat
HIV prevention efforts amplified through music at SXSW, Gilead Sciences asserts - Traders Union
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals - simplywall.st
Gilead Sciences, Inc. $GILD Stake Boosted by SageView Advisory Group LLC - MarketBeat
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Bokf Na Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index - Kalkine Media
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
News | British Land and Royal London sign Gilead at Euston development - CoStar
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead Sciences, Inc. $GILD Shares Sold by Mackenzie Financial Corp - MarketBeat
Magnetar Financial LLC Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead at Leerink Conference: Strategic Expansion in Healthcare - Investing.com India
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Jefferies Initiates Coverage on Gilead Sciences (GILD) with 'Buy' Rating | GILD Stock News - GuruFocus
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
What 16 Analyst Ratings Have To Say About Gilead Sciences - Benzinga
Gilead Sciences (NASDAQ:GILD) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Gilead price boosted by important supportForecast today10-03-2026 - Economies.com
Gilead Sciences, Inc. $GILD Shares Sold by Richard Bernstein Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Decreased by Capital Research Global Investors - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Trimmed by Capital World Investors - MarketBeat
Capital International Inc. CA Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Jefferies initiates Gilead Sciences stock with buy rating By Investing.com - Investing.com Canada
Legal & General Group Plc Buys 414,454 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Russell Investments Group Ltd. Sells 49,215 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fieldview Capital Management LLC Invests $1.91 Million in Gilead Sciences, Inc. $GILD - MarketBeat
GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors - ChartMill
Jefferies initiates Gilead Sciences stock with buy rating - Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Insider Monkey
Banque Cantonale Vaudoise Has $8.91 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance
How Low Can Gilead Sciences Stock Really Go? - Trefis
Swiss National Bank Has $398 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Has $230.08 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by WINTON GROUP Ltd - MarketBeat
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):